Do analysts recommend AVNS or CERS?

Cerus has a consensus target price of $4.00, suggesting a potential upside of 42.15%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is AVNS or CERS more profitable?

Cerus has a net margin of -3.06% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Avanos Medical -10.39% 5.39% 3.97% Cerus -3.06% -10.19% -3.14%

Does the media prefer AVNS or CERS?

In the previous week, Cerus had 1 more articles in the media than Avanos Medical. MarketBeat recorded 3 mentions for Cerus and 2 mentions for Avanos Medical. Cerus' average media sentiment score of 1.19 beat Avanos Medical's score of 1.16 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avanos Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CERS or QDEL more profitable?

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% QuidelOrtho -39.20% 4.88% 1.63%

Does the media favor CERS or QDEL?

In the previous week, QuidelOrtho had 8 more articles in the media than Cerus. MarketBeat recorded 11 mentions for QuidelOrtho and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat QuidelOrtho's score of 0.56 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QuidelOrtho 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CERS or SMTI?

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.75 -$15.63M -$0.03 N/A Sanara MedTech $103.12M 3.04 -$37.56M -$3.77 N/A

Is CERS or SMTI more profitable?

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 31.56% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Sanara MedTech -29.15% 31.56% 2.82%

Does the media refer more to CERS or SMTI?

In the previous week, Sanara MedTech had 6 more articles in the media than Cerus. MarketBeat recorded 9 mentions for Sanara MedTech and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat Sanara MedTech's score of 0.23 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CERS or EMBC?

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.75 -$15.63M -$0.03 N/A Embecta $1.08B 0.27 $95.40M $1.48 3.46

Is CERS or EMBC more profitable?

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Embecta 8.59% -19.25% 10.82%

Does the media favor CERS or EMBC?

In the previous week, Embecta had 41 more articles in the media than Cerus. MarketBeat recorded 44 mentions for Embecta and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat Embecta's score of 0.32 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 4 Very Positive mention(s) 1 Positive mention(s) 32 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, CERS or RXST?

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.75 -$15.63M -$0.03 N/A RxSight $134.48M 2.15 -$38.94M -$1.13 N/A

Is CERS or RXST more profitable?

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% RxSight -36.80% -17.35% -14.70%

Does the media prefer CERS or RXST?

In the previous week, RxSight had 8 more articles in the media than Cerus. MarketBeat recorded 11 mentions for RxSight and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat RxSight's score of 0.15 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Cerus (CERS) Competitors

$2.81 -0.03 (-0.92%)

As of 09:42 AM Eastern

Compare

CERS vs. AVNS, QDEL, SMTI, EMBC, and RXST

Should you buy Cerus stock or one of its competitors? Cerus's main competitors and comparable companies include Avanos Medical (AVNS), QuidelOrtho (QDEL), Sanara MedTech (SMTI), Embecta (EMBC), and RxSight (RXST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Cerus compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Cerus has a consensus target price of $4.00, suggesting a potential upside of 42.15%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Avanos Medical has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Cerus has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Cerus has a net margin of -3.06% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
Cerus	-3.06%	-10.19%	-3.14%

Cerus has lower revenue, but higher earnings than Avanos Medical. Cerus is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A
Cerus	$206.13M	2.75	-$15.63M	-$0.03	N/A

In the previous week, Cerus had 1 more articles in the media than Avanos Medical. MarketBeat recorded 3 mentions for Cerus and 2 mentions for Avanos Medical. Cerus' average media sentiment score of 1.19 beat Avanos Medical's score of 1.16 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avanos Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 2.3% of Avanos Medical shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cerus beats Avanos Medical on 11 of the 16 factors compared between the two stocks.

How does Cerus compare to QuidelOrtho?

Cerus (NASDAQ:CERS) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Cerus has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
QuidelOrtho	-39.20%	4.88%	1.63%

78.4% of Cerus shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, QuidelOrtho had 8 more articles in the media than Cerus. MarketBeat recorded 11 mentions for QuidelOrtho and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat QuidelOrtho's score of 0.56 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QuidelOrtho	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus presently has a consensus target price of $4.00, suggesting a potential upside of 42.15%. QuidelOrtho has a consensus target price of $13.63, suggesting a potential downside of 8.69%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts plainly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cerus has higher earnings, but lower revenue than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.75	-$15.63M	-$0.03	N/A
QuidelOrtho	$2.73B	0.37	-$1.13B	-$15.41	N/A

Summary

Cerus beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

How does Cerus compare to Sanara MedTech?

Cerus (NASDAQ:CERS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 31.56% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Sanara MedTech	-29.15%	31.56%	2.82%

Cerus currently has a consensus price target of $4.00, suggesting a potential upside of 42.15%. Sanara MedTech has a consensus price target of $35.00, suggesting a potential upside of 2.59%. Given Cerus' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cerus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Cerus has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

In the previous week, Sanara MedTech had 6 more articles in the media than Cerus. MarketBeat recorded 9 mentions for Sanara MedTech and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat Sanara MedTech's score of 0.23 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

78.4% of Cerus shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 5.3% of Cerus shares are owned by company insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.75	-$15.63M	-$0.03	N/A
Sanara MedTech	$103.12M	3.04	-$37.56M	-$3.77	N/A

Summary

Cerus beats Sanara MedTech on 10 of the 16 factors compared between the two stocks.

How does Cerus compare to Embecta?

Cerus (NASDAQ:CERS) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.75	-$15.63M	-$0.03	N/A
Embecta	$1.08B	0.27	$95.40M	$1.48	3.46

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Embecta	8.59%	-19.25%	10.82%

In the previous week, Embecta had 41 more articles in the media than Cerus. MarketBeat recorded 44 mentions for Embecta and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat Embecta's score of 0.32 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	4 Very Positive mention(s)	1 Positive mention(s)	32 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cerus presently has a consensus target price of $4.00, indicating a potential upside of 42.15%. Embecta has a consensus target price of $11.00, indicating a potential upside of 115.05%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than Cerus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Cerus has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Embecta has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

78.4% of Cerus shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Embecta beats Cerus on 9 of the 16 factors compared between the two stocks.

How does Cerus compare to RxSight?

Cerus (NASDAQ:CERS) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Cerus has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, RxSight has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.75	-$15.63M	-$0.03	N/A
RxSight	$134.48M	2.15	-$38.94M	-$1.13	N/A

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
RxSight	-36.80%	-17.35%	-14.70%

Cerus currently has a consensus price target of $4.00, indicating a potential upside of 42.15%. RxSight has a consensus price target of $8.37, indicating a potential upside of 20.28%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

In the previous week, RxSight had 8 more articles in the media than Cerus. MarketBeat recorded 11 mentions for RxSight and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat RxSight's score of 0.15 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.4% of Cerus shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cerus beats RxSight on 11 of the 15 factors compared between the two stocks.

Get Cerus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERS vs. The Competition

Export

Metric	Cerus	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$567.08M	$5.94B	$7.07B	$13.00B
Dividend Yield	N/A	1.76%	2.58%	10.72%
P/E Ratio	-93.80	26.47	269.63	25.21
Price / Sales	2.75	40.69	596.70	99.90
Price / Cash	N/A	33.59	70.53	50.75
Price / Book	8.04	5.90	13.11	6.24
Net Income	-$15.63M	$148.67M	$3.45B	$347.70M
7 Day Performance	19.74%	1.87%	0.77%	0.87%
1 Month Performance	-8.34%	4.66%	1.44%	0.90%
1 Year Performance	121.57%	8.98%	67.07%	20.13%

Cerus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERS Cerus	2.1132 of 5 stars	$2.81 -0.9%	$4.00 +42.1%	+113.5%	$567.08M	$206.13M	N/A	290
AVNS Avanos Medical	1.3225 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	2,287
QDEL QuidelOrtho	1.5287 of 5 stars	$13.63 -0.9%	$13.63	-44.3%	$928.68M	$2.73B	N/A	6,500	Analyst Downgrade
SMTI Sanara MedTech	1.5882 of 5 stars	$34.21 -0.1%	$35.00 +2.3%	+7.0%	$313.42M	$103.12M	N/A	60	Earnings Report Analyst Upgrade Short Interest Decrease
EMBC Embecta	3.8763 of 5 stars	$5.07 +1.5%	$11.00 +117.2%	-63.3%	$299.91M	$1.08B	3.42	1,850	Trending News Earnings Report Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cerus (CERS) Competitors

CERS vs. AVNS, QDEL, SMTI, EMBC, and RXST

How does Cerus compare to Avanos Medical?

Summary

How does Cerus compare to QuidelOrtho?

Summary

How does Cerus compare to Sanara MedTech?

Summary

How does Cerus compare to Embecta?

Summary

How does Cerus compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cerus (CERS) Competitors

CERS vs. AVNS, QDEL, SMTI, EMBC, and RXST

How does Cerus compare to Avanos Medical?

Do analysts recommend AVNS or CERS?

Which has more volatility and risk, AVNS or CERS?

Is AVNS or CERS more profitable?

Which has stronger earnings & valuation, AVNS or CERS?

Does the media prefer AVNS or CERS?

Do institutionals and insiders hold more shares of AVNS or CERS?

Summary

How does Cerus compare to QuidelOrtho?

Which has more volatility and risk, CERS or QDEL?

Is CERS or QDEL more profitable?

Do insiders and institutionals have more ownership in CERS or QDEL?

Does the media favor CERS or QDEL?

Do analysts prefer CERS or QDEL?

Which has higher earnings & valuation, CERS or QDEL?

Summary

How does Cerus compare to Sanara MedTech?

Is CERS or SMTI more profitable?

Do analysts prefer CERS or SMTI?

Which has more risk & volatility, CERS or SMTI?

Does the media refer more to CERS or SMTI?

Do insiders & institutionals have more ownership in CERS or SMTI?

Which has preferable valuation & earnings, CERS or SMTI?

Summary

How does Cerus compare to Embecta?

Which has stronger earnings & valuation, CERS or EMBC?

Is CERS or EMBC more profitable?

Does the media favor CERS or EMBC?

Do analysts recommend CERS or EMBC?

Which has more risk & volatility, CERS or EMBC?

Do institutionals and insiders have more ownership in CERS or EMBC?

Summary

How does Cerus compare to RxSight?

Which has more volatility and risk, CERS or RXST?

Which has stronger valuation & earnings, CERS or RXST?

Is CERS or RXST more profitable?

Do analysts recommend CERS or RXST?

Does the media prefer CERS or RXST?

Do institutionals and insiders believe in CERS or RXST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools